BioCryst Presents New Analyses Of BCX4208 Phase 2 Studies In Patients With Gout At The Annual European Congress Of Rheumatology

Podiatry Arena BioCryst Presents New Analyses Of BCX4208 Phase 2 Studies In Patients With Gout At The Annual European Congress Of Rheumatology

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

BioCryst Presents New Analyses Of BCX4208 Phase 2 Studies In Patients With Gout At The Annual European Congress Of Rheumatology

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

27th May 2011, 10:20 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 10,247

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 22 Times in 22 Posts

BioCryst Presents New Analyses Of BCX4208 Phase 2 Studies In Patients With Gout At The Annual European Congress Of Rheumatology

Podiatry Arena members do not see these ads

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, U.K...

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
TreatmentTrends®: European Gout Study Highlights Current Treatment Patterns And Unmet Need For New Gout Therapies Among Rheumatologists	RSSFeedBot	Latest Rheumatology News	0	9th December 2010 10:10 AM
VBL Presents Positive Preclinical Data On Immune Modulator In Rheumatoid Arthritis At EULAR Annual Meeting	RSSFeedBot	Latest Rheumatology News	0	20th June 2010 03:21 AM
BioCryst Announces Initiation of Phase 2 Study of BCX4208 for the Treatment of Gout	RSSFeedBot	Gout Online	0	30th September 2009 11:20 PM
ACTEMRA(R) (tocilizumab) Studies To Be Featured At American College Of Rheumatology Annual Scientific Meeting	RSSFeedBot	Latest Rheumatology News	0	21st October 2008 04:10 AM
BioCryst Reports Results From BCX-4208 Phase IIa Trial In Subjects With Psoriasis	RSSFeedBot	Latest Dermatology News	0	5th September 2008 07:01 AM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 04:00 AM.

User Name		Remember Me?
Password